|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007138,
umls-concept:C0007600,
umls-concept:C0018270,
umls-concept:C0034802,
umls-concept:C0851827,
umls-concept:C1122962,
umls-concept:C1155551,
umls-concept:C1269955,
umls-concept:C1514758,
umls-concept:C1518174,
umls-concept:C1701901,
umls-concept:C2699153
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-5-5
|
|
pubmed:abstractText |
Abnormally high levels of epidermal growth factor receptor (EGFR) protein are associated with advanced tumor stage/grade. The objective of this study was to evaluate the effects of the specific EGFR tyrosine kinase inhibitor gefitinib on activation of the Akt and mitogen-activated protein kinase (MAPK) pathways in human urothelial cell carcinoma (UCC) cell lines and to identify potential markers of gefitinib responsiveness in biopsy samples of UCC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AbbouClaude CCC,
pubmed-author:BakkarAshrafA,
pubmed-author:ChopinDominique KDK,
pubmed-author:DaherAhmadA,
pubmed-author:LoricSylvainS,
pubmed-author:MailléPascaleP,
pubmed-author:NicolleGaëlleG,
pubmed-author:RadvanyiFrançoisF,
pubmed-author:ThieryJean-PaulJP,
pubmed-author:VacherotFrancisF,
pubmed-author:Van der KwastTheodoreT,
pubmed-author:VermeyMarcelM,
pubmed-author:VordosDimitriosD,
pubmed-author:WallerandHervéH,
pubmed-author:de MedinaSixtina Gil DiezSG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2937-43
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16675591-Cell Division,
pubmed-meshheading:16675591-Cell Line, Tumor,
pubmed-meshheading:16675591-Enzyme Activation,
pubmed-meshheading:16675591-Humans,
pubmed-meshheading:16675591-Mitogen-Activated Protein Kinase Kinases,
pubmed-meshheading:16675591-Neoplasm Invasiveness,
pubmed-meshheading:16675591-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:16675591-Quinazolines,
pubmed-meshheading:16675591-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16675591-Urologic Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.
|
|
pubmed:affiliation |
Institut National de la Sante et de la Recherche Medicale, EMI 03-37, Faculté de Médecine, Université Paris XII, Créteil, France. gaelle_nicolle@yahoo.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
